Chronic autoimmune urticaria in children

Srebrnjak Children's Hospital, Reference Center for Pediatric Allergology of the Ministry of Health and Social Welfare, Srebrnjak 100, HR-10000 Zagreb, Croatia.
Acta dermatovenerologica Croatica: ADC / Hrvatsko dermatolosko drustvo (Impact Factor: 0.43). 06/2008; 16(2):65-71.
Source: PubMed


Results of determination of circulating histamine releasing autoantibodies using histamine release urticaria test in 12 children (aged 3 to 18 years, mean age 8.5 years; 7 female and 5 male) with chronic urticaria are presented. Standard work-up including detailed history, allergy testing and routine laboratory findings did not disclose any plausible cause of chronic/recurrent urticarial eruption in these children. All children underwent serum-induced basophil histamine release urticaria test. At serum dilution of 12.5%, the mean percent of histamine liberation was 40.8% (range 18%-77%; normal <16.5%), which indicated the presence of autoantibodies to Fc epsilon RI and/or to the IgE-Fc epsilon RI complex. The percent of histamine release did not correlate with patient age or duration and severity of symptoms. Thus the autoimmune basis of chronic urticaria was established. Associated antithyroid autoantibodies were found in two patients. Complete or partial remission was obtained with treatment that included antihistamines, low salicylate-low preservative diet in all, and high dose intravenous immunoglobulin in 3 children.

Download full-text


Available from: Slavica Dodig,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intravenous immunoglobulins (IVIGs) are the mainstay of treatment in children with Kawasaki syndrome, primary immunodeficiency syndromes and idiopathic (immune-mediated) thrombocytopenic purpura. Where the US FDA has approved the use of IVIGs for the above indications, the last 10 years have seen a boom in off-label use of IVIGs in a number of autoimmune and cell-mediated diseases in dermatology. The high cost of IVIGs is often considered to be a disadvantage that restricts their use and is often debated. We feel that taking into account the high safety profile with low incidence of side effects related to the use of IVIGs, the benefits achieved in the diseases they are often used to treat, prevention and/or a decrease in the side effects related to chronic use of systemic steroids and other immunosuppressants in most of these disorders and, above all, the improvement in quality of life through functional improvement, their use surpasses the cost issue and is justified. After a brief review of the mechanism of action, pharmacokinetics, doses and side effects of IVIGs, we will focus mainly on the indications of IVIGs in pediatric dermatology and address whether their use is justified for these indications.
    Expert Review of Dermatology 01/2009; 4(1):37-45. DOI:10.1586/17469872.4.1.37
  • [Show abstract] [Hide abstract]
    ABSTRACT: It is well-recognized that 30-40% of chronic idiopathic urticaria is autoimmune in nature. Chronic autoimmune urticaria is caused by anti-FcepsilonRI and less frequently, by anti-IgE autoantibodies that lead to mast cell and basophil activation, thereby giving rise to the release of histamine and other proinflammatory mediators. Activation of the classical complement pathway and formation of C5a are important in dermal mast cell activation. C5a is also a neutrophil and eosinophil chemoattractant. Chronic autoimmune urticaria has been found to be associated with autoimmune thyroid disease. The autologous serum skin test is used as a screening test for chronic autoimmune urticaria and has a sensitivity and specificity of about 70 and 80%, respectively. The current gold standard diagnostic test is the basophil histamine release assay. The treatment of chronic autoimmune urticaria, as in chronic idiopathic urticaria, is with H1 antihistamines. Oral corticosteroids may be used during acute flares. Refractory cases have been shown to respond to cyclosporine and other immunomodulators. The prevalence of chronic autoimmune urticaria in Singapore is similar to that reported in Western countries at about 42%. The presence of thyroid autoimmunity appears to be higher than reported, with 22.5% of patients with chronic idiopathic urticaria here, exhibiting presence of thyroid autoantibodies.
    Indian Journal of Dermatology 07/2009; 54(3):269-74. DOI:10.4103/0019-5154.55640
  • [Show abstract] [Hide abstract]
    ABSTRACT: Chronic urticaria (daily or almost daily symptoms lasting for more than six weeks) is characterized by wheals and erythema, with or without itching. A few case reports have shown chronic autoimmune urticaria at the beginning of systemic lupus erythematosus (SLE), particularly in adults. However, the prevalence of this manifestation in a lupus paediatric population was not studied. During 27 consecutive years, 5419 patients were followed up at our University Hospital and 271 (5%) had juvenile SLE (American College of Rheumatology criteria). Two of them (0.7%) had chronic and painless autoimmune urticaria as the first manifestation of juvenile SLE, and were reported herein. One case was a five-year old female with continuous widespread urticaria (duration 120 days), antinuclear antibodies (ANA) 1:640 (dense fine speckled pattern) and elevated complement levels. The juvenile SLE diagnosis was established after one year. The other case was a 13-year old female who had chronic widespread urticaria (lasting 45 days), ANA 1:160 (fine speckled pattern) and normal complement levels. The juvenile SLE diagnosis was established after three years. In conclusion, chronic autoimmune urticaria is very rare and may be the first lupus manifestation, particularly associated with the presence of autoantibodies. This study reinforces the importance of a rigorous follow-up in children and adolescents suffering from autoimmune urticaria due to the possibility of connective tissue disorders, such as paediatric lupus.
    Lupus 12/2010; 20(7):763-6. DOI:10.1177/0961203310392428 · 2.20 Impact Factor
Show more